Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CD38 inhibitor
DRUG CLASS:
CD38 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
›
Associations
(51)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive: A1 - Approval
isatuximab-irfc
Sensitive
:
A1
isatuximab-irfc
Sensitive: A1 - Approval
isatuximab-irfc
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
lenalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + daratumumab
Sensitive: A1 - Approval
lenalidomide + daratumumab
Sensitive
:
A1
lenalidomide + daratumumab
Sensitive: A1 - Approval
lenalidomide + daratumumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
daratumumab and hyaluronidase-fihj
Sensitive
:
A1
daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
daratumumab and hyaluronidase-fihj
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: A1 - Approval
pomalidomide + isatuximab-irfc
Sensitive
:
A1
pomalidomide + isatuximab-irfc
Sensitive: A1 - Approval
pomalidomide + isatuximab-irfc
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab + pomalidomide
Sensitive: A1 - Approval
daratumumab + pomalidomide
Sensitive
:
A1
daratumumab + pomalidomide
Sensitive: A1 - Approval
daratumumab + pomalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab
Sensitive: A1 - Approval
daratumumab
Sensitive
:
A1
daratumumab
Sensitive: A1 - Approval
daratumumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
daratumumab + thalidomide
Sensitive: A1 - Approval
daratumumab + thalidomide
Sensitive
:
A1
daratumumab + thalidomide
Sensitive: A1 - Approval
daratumumab + thalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
thalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive: A1 - Approval
pomalidomide + daratumumab and hyaluronidase-fihj
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
selinexor + daratumumab
Sensitive: A2 - Guideline
selinexor + daratumumab
Sensitive
:
A2
selinexor + daratumumab
Sensitive: A2 - Guideline
selinexor + daratumumab
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
daratumumab
Sensitive: A2 - Guideline
daratumumab
Sensitive
:
A2
daratumumab
Sensitive: A2 - Guideline
daratumumab
Sensitive
:
A2
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
Chr t(4;14)
Multiple Myeloma
Chr t(4;14)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
Chr amplification(1)(q21)
Multiple Myeloma
Chr amplification(1)(q21)
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: B - Late Trials
pomalidomide + isatuximab-irfc
Sensitive
:
B
pomalidomide + isatuximab-irfc
Sensitive: B - Late Trials
pomalidomide + isatuximab-irfc
Sensitive
:
B
Chr amplification(1)(q21)
Multiple Myeloma
Chr amplification(1)(q21)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
Chr t(4;14)
Multiple Myeloma
Chr t(4;14)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
PTPRC expression
Multiple Myeloma
PTPRC expression
Multiple Myeloma
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
CD200 expression
Multiple Myeloma
CD200 expression
Multiple Myeloma
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
CD27 expression
Multiple Myeloma
CD27 expression
Multiple Myeloma
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
CD38 overexpression
Multiple Myeloma
CD38 overexpression
Multiple Myeloma
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
CD38 expression
Waldenstrom Macroglobulinemia
CD38 expression
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
CXCR4 mutation
Waldenstrom Macroglobulinemia
CXCR4 mutation
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
CD20 expression
Lymphoma
CD20 expression
Lymphoma
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
CD38 expression
Lymphoma
CD38 expression
Lymphoma
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
BHV-1100
Sensitive: C3 – Early Trials
BHV-1100
Sensitive
:
C3
BHV-1100
Sensitive: C3 – Early Trials
BHV-1100
Sensitive
:
C3
CD38 positive
Multiple Myeloma
CD38 positive
Multiple Myeloma
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login